Subtype
Benign Peripheral Nervous System Neoplasm
CI-CAN-00000532Explore in graph →
Non-malignant21 active trials2 evidence items
- NCIt
- C213862
Loading cancer entity…
Subtype
CI-CAN-00000532Explore in graph →
Clinical trials
61 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01362803 | AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | active not recruiting | Phase 1 / Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02390752 | Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... | recruiting | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 |
| Aug 24, 2026 |
| clinicaltrials |
| NCT06502171 | Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas(NF113) | recruiting | Phase 1 | 30 | Girish Dhall, MDOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04590235 | A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | active not recruiting | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07102394 | Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 | recruiting | Phase 1 | 10 | Johns Hopkins UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06300502 | Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs) | enrolling by invitation | Phase 1 | 15 | Massachusetts General HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06159166 | Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).(Mirda) | recruiting | Phase 1 / Phase 2 | 24 | Johns Hopkins UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | recruiting | Phase 1 | 56 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT07024394 | Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 | not yet recruiting | Phase 1 / Phase 2 | 65 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT04730583 | Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04954001 | Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | active not recruiting | Phase 1 / Phase 2 | 160 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 3 | Nov 12, 2024 | clinicaltrials |
| NCT05438290 | DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | completed | Phase 1 | 17 | Nicholas GulatiOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03326388 | Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours(INSPECT) | completed | Phase 1 / Phase 2 | 14 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT00727233 | Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01140360 | Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas(0908-09) | completed | Phase 1 / Phase 2 | 21 | Kent RobertsonOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01999270 | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Oct 21, 2016 | clinicaltrials |
| NCT00716469 | Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas(PDT) | terminated | Phase 1 | 7 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01031901 | Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) | completed | Phase 1 | 52 | The University of Texas Health Science Center, HoustonOTHER | 1 | Feb 27, 2012 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials